Company intelligence / Profile preview
Biotest AG
- Ownership
- Public · BIO
- Employees
- ~2495
- Development stage
- Phase 3
Overview
Biotest AG develops and markets plasma protein products and biotherapeutic drugs. Its portfolio includes approved therapies for immune deficiencies and bleeding disorders. Recent milestones include FDA approval of Yimmugo for primary antibody deficiencies in 2024.
- Therapeutic areas
- OtherHematologyImmunology
- Modalities
- Plasma-derived proteins (immunoglobulins, clotting factors, albumin)monoclonal antibodies
- Industry
- Biotech
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $10.2B
- Total revenue
- $651M
- Enterprise value
- $9.8B
Beyond the preview
Go deeper on Biotest AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biotest AG.